Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing
Reexamination Certificate
2011-01-11
2011-01-11
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
C435S320100
Reexamination Certificate
active
07867483
ABSTRACT:
The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
REFERENCES:
patent: 6045802 (2000-04-01), Schlom et al.
patent: 6165460 (2000-12-01), Schlom et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6913752 (2005-07-01), Chaplin et al.
patent: 7005498 (2006-02-01), Steinaa et al.
patent: 7414108 (2008-08-01), Laus et al.
patent: WO 98/46769 (1998-10-01), None
patent: WO03097845 (2003-11-01), None
patent: WO 2005/019464 (2005-03-01), None
Obasaju et al. Hematol-Oncol-Clin-North-Am. Jun. 2001; 15(3): 525-45, Abstract only.
Mandl et al., MVA-BN-HER2: A Novel Vaccine for the Treatment of Breast Cancers Which Overexpress HER-2, J. Immunother. 29(6):652, 2006.
Mandl et al., MVA-BN-PRO: A Novel Immunotherapeutic for the Treatment of Prostate Cancer, J. Immunother. 30 (8):898, 2007.
Gulley et al., Phase I Study of a Vaccine Using Recombinant Vaccinia Virus Expressing PSA (rV-PSA) in Patients With Metastatic Androgen-Independent Prostate Cancer, The Prostate 53:109-117, 2002.
Eder et al., A Phase I Trial of a Recombinant Vaccinia Virus Expressing Prostate-specific Antigen in Advanced Prostate Cancer, Clinical Cancer Research 6:1632-1638, 2000.
Taichman et al., The evolving biology and treatment of prostate cancer, The Journal of Clinical Investigation 117, 2351-2361, 2007.
Webster et al., Prostate Cancer immunology: Biology, Therapeutics, and Challenges, Journal of Cinical Oncology 23, 8262-8269, 2005.
Harrop et al., Viral Vectors for Cancer Immunotherapy, Frontiers in Bioscience 11, 804-817, 2006.
Arlen et al., Pox Viral Vaccine Approaches, Semin Oncol 32:549-555, 2005.
Liu et al., Gene-based vaccines and immunotherapeutics, Proc. Natl. Acad. Sci. 101 (suppl. 2) 14567-14571, 2004.
Amato et al., 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy, Expert Opin. Biol. Ther. 7(9):1463-1469, 2007.
Taichman et al., The evolving biology and treatment of prostate cancer, The Journal of Clinical Investigation 117 (9) 2351-2361, 2007.
Webster et al., Prostate cancer Immunology: Biology, Therapeutics, and Challenges, Journal of Clinical Oncology 23 (32) 8262-8269 (2005).
McNeel, Prostate cancer immunotherapy, Current Opinion in Urology 17:175-181, 2007.
Nelson, Prostate cancer prevention, Current Opinion in Urology 17:157-167, 2007.
Waeckerle-Men et al., Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma, Cancer Immunol Immunother 55: 1524-1533, 2006.
Machlenkin et al., Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice, Cancer Immunol Immunother 56:217-226, 2007.
Valone et al., Dendritic cell-based treatment of cancer: closing in on a cellular therapy, The Cancer Journal 7 (Suppl. 2):S53-61, 2001.
Fong et al., Induction of Tissue-Specific Autoimmune Prostatitis with Prostatic Acid Phosphatase Immunization, The Journal of Immunology 159: 3113-3117, 1997.
Fong et al., Dendritic Cell-Based Xenoantigen Vaccination for Prostate Cancer Immunotherapy, The Journal of Immunology 167: 7150-7156, 2001.
Johnson et al., Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP), Vaccine 24: 293-303, 2006.
Johnson et al., Plasmid DNA vaccine encoding prostatic acid phosphatase is effective in eliciting autologous antigen-specific CD8+ T cells, Cancer Immunol Immunother 56:885-895, 2007.
Delcayre Alain
Laus Reiner
Legrand Fatema
Mandl Stefanie
Rountree Ryan Blair
BN Immunotherapeutics, Inc.
Law Office of Salvatore Arrigo
Li Bao
Lucas Zachariah
LandOfFree
Use of MVA to treat prostate cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of MVA to treat prostate cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of MVA to treat prostate cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2703019